GlassScriptPhysician profile
Stephen N Zoretic
NPI 1295703890
$1,852.35
in general payments reported to CMS, 2019-2025
27 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $90.33 · 2021: $99.99 · 2022: $203 · 2023: $510 · 2024: $209 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050 · Education: $82.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.34 |
| Education | $82.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $350.23 | 2019-2024 | Myrbetriq, Xtandi |
| Sumitomo Pharma America, INC. | $201.71 | 2023-2025 | Gemtesa, Orgovyx |
| Progenics Pharmaceuticals, INC. | $183.89 | 2023-2025 | Pylarify |
| Glaxosmithkline, LLC. | $162.76 | 2019-2024 | Trelegy Ellipta |
| Biotissue Holdings INC. | $138.58 | 2025 | |
| Antares Pharma, INC. | $127.02 | 2019-2025 | Xyosted |
| Tolmar, INC. | $87.03 | 2024-2025 | Eligard, Jatenzo |
| Pfizer INC. | $69.79 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $56.00 | 2019-2025 | Adstiladrin |
| Janssen Pharmaceuticals, INC | $52.26 | 2019-2020 | |
| Amgen INC. | $43.72 | 2022-2023 | Prolia, Evenity |
| Urogen Pharma, INC. | $42.35 | 2022-2025 | |
| Myovant Sciences INC. | $40.15 | 2022 | |
| Dendreon Pharmaceuticals LLC | $39.06 | 2019-2023 | Provenge |
| 180 Medical, INC. | $37.95 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $30.79 | 2023 | Bulkamid, Axonics |
| Teleflex LLC | $24.79 | 2025 | Barrigel |
| Olympus America INC. | $23.73 | 2024 | Itind System |
| Avation Medical, INC. | $22.04 | 2024 | Vivally |
| Endo USA, INC. | $18.40 | 2025 | Aveed, Xiaflex |
| Halozyme INC | $16.84 | 2023 | |
| Accord Healthcare, INC. | $16.44 | 2023 | |
| Novo Nordisk INC | $15.84 | 2023 | Ozempic, Rybelsus |
| Aytu Biopharma, INC. | $13.23 | 2019 | |
| Lilly USA, LLC | $13.18 | 2023 | Mounjaro |
| Allergan, INC. | $12.46 | 2019 | |
| Endo Pharmaceuticals INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Zoretic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.